Neuropathix Quick Ratio (TYGS) starting from the first quarter 2022 to first quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Neuropathix Inc.  (TYGS)

Neuropathix's Quick Ratio

TYGS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Neuropathix's Cash & cash equivalent grew by 263.79 % in the Q1 2022 sequentially, faster than Current Liabilities, this led to improvement in Neuropathix's Quick Ratio to 0.03, Quick Ratio remained below Neuropathix Inc. average.

Within Major Pharmaceutical Preparations industry 605 other companies have achieved higher Quick Ratio than Neuropathix in first quarter 2022. While Quick Ratio total ranking has improved so far during the Q1 2022 to 5790, from total ranking in the fourth quarter 2021 at 6050.

Explain Quick Ratio?
How much Cash & cash equivalents TYGS´s has?
What are TYGS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TYGS Quick Ratio (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1
Y / Y Current Liabilities Change 47.4 % 83.08 % 26.63 % 15.15 % 53.7 %
Y / Y Cash & cash equivalent Change -64.94 % -15.89 % -28.02 % -58.83 % 158.39 %
Quick Ratio MRQ 0.03 0.01 0.01 0.03 0.14
TYGS's Total Ranking # 5790 # 6050 # 5319 # 5854 # 4980
Seq. Current Liabilities Change 20.63 % 12.6 % 5.29 % 3.06 % 49.83 %
Seq. Cash & cash equivalent Change 263.79 % 44.33 % -66.66 % -79.97 % 772.7 %



Quick Ratio first quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 606
Healthcare Sector # 1228
Overall Market # 5790


Quick Ratio Statistics
High Average Low
9.04 1.51 0
(Mar 31 2018)   (Jun 30 2017)




Financial Statements
Neuropathix's Current Liabilities $ 4 Millions Visit TYGS's Balance sheet
Neuropathix's Cash & cash equivalent $ 0 Millions Visit TYGS's Balance sheet
Source of TYGS's Sales Visit TYGS's Sales by Geography


Cumulative Neuropathix's Quick Ratio

TYGS's Quick Ratio for the trailling 12 Months

TYGS Quick Ratio

 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 40.72 % 41.29 % 28.4 % 53.35 % 107.61 %
Y / Y Cash & cash equivalent TTM Growth -57.84 % 26.16 % 0.6 % -81.12 % -89.04 %
Quick Ratio TTM 0.02 0.04 0.05 0.06 0.07
Total Ranking TTM # 5433 # 5551 # 4451 # 4378 # 4268
Seq. Current Liabilities TTM Growth 10.93 % 14.66 % 6.42 % 3.97 % 11.38 %
Seq. Cash & cash equivalent TTM Growth -47.63 % -1.32 % -1.85 % -16.89 % 56.72 %

Quick ratio ranking by company, industry and sector >> Back to TYGS Financial Strength Comparisons >> Go to Compare TYGS Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2022 to $3.60 millions, cumulative Quick Ratio decreased to 0.02 below the Neuropathix Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 597 other companies have achieved higher Quick Ratio than Neuropathix. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2021 from 4953 to 6031.

Explain Quick Ratio?
How much Cash & cash equivalents TYGS´s has?
What are TYGS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 598
Healthcare Sector # 1201
Within the Market # 5790


trailing twelve months Quick Ratio Statistics
High Average Low
0.75 0.28 0.02
(Jun 30 2018)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2022 MRQ Cash & cash equivalentMar 31 2022 MRQ Current Liabilities
International Stem Cell Corporation  0.08 $ 0.398  Millions$ 4.811  Millions
Viatris Inc   0.08 $ 752.400  Millions$ 9,642.900  Millions
Inhibitor Therapeutics Inc   0.07 $ 0.036  Millions$ 0.492  Millions
Orgenesis Inc   0.07 $ 1.123  Millions$ 15.253  Millions
Sangui Biotech International Inc  0.07 $ 0.068  Millions$ 0.976  Millions
Northwest Biotherapeutics Inc  0.05 $ 6.963  Millions$ 130.012  Millions
Semnur Pharmaceuticals Inc   0.05 $ 0.017  Millions$ 0.348  Millions
Cell Source Inc   0.05 $ 0.132  Millions$ 2.789  Millions
Innovation1 Biotech Inc   0.05 $ 1.370  Millions$ 29.276  Millions
Propanc Biopharma Inc   0.04 $ 0.134  Millions$ 3.117  Millions
Intellipharmaceutics International Inc   0.04 $ 0.211  Millions$ 5.195  Millions
Biostax Corp  0.04 $ 0.437  Millions$ 11.304  Millions
Bioadaptives Inc   0.04 $ 0.056  Millions$ 1.485  Millions
Apexigen Inc   0.04 $ 0.093  Millions$ 2.604  Millions
Neuropathix Inc.  0.03 $ 0.119  Millions$ 3.598  Millions
Integrated Biopharma Inc  0.03 $ 0.264  Millions$ 9.233  Millions
Emmaus Life Sciences Inc   0.02 $ 0.813  Millions$ 34.551  Millions
Kaya Holdings Inc   0.02 $ 0.203  Millions$ 8.769  Millions
Provectus Biopharmaceuticals Inc   0.02 $ 0.174  Millions$ 7.825  Millions
Statera Biopharma Inc fka Cytocom Inc   0.02 $ 0.331  Millions$ 15.073  Millions
Wellness Center Usa Inc  0.02 $ 0.064  Millions$ 2.959  Millions
Q Biomed inc   0.02 $ 0.137  Millions$ 6.368  Millions
Avenir Wellness Solutions Inc   0.02 $ 0.531  Millions$ 25.060  Millions
Evofem Biosciences Inc   0.02 $ 2.761  Millions$ 154.474  Millions
Sunwin Stevia International Inc.  0.01 $ 0.321  Millions$ 22.005  Millions
Novaccess Global Inc  0.01 $ 0.062  Millions$ 4.516  Millions
Actavia Life Sciences Inc   0.01 $ 0.028  Millions$ 2.174  Millions
Cytodyn inc   0.01 $ 1.363  Millions$ 106.532  Millions
Oncotelic Therapeutics Inc   0.01 $ 0.098  Millions$ 8.555  Millions
Musclepharm Corporation  0.01 $ 0.534  Millions$ 48.171  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.